Research
Hormonal
Newer glucose-lowering agents (ultra-long-acting insulin analogs, SGLT2 inhibitors, GLP-1 RAs) reduce Glycemic Variability (GV) and hypoglycemia risk compared to older agents (e.g., insulin glargine 100U/mL) due to smoother pharmacodynamic profiles.
If you experience high glucose swings or frequent lows on older insulin, discuss switching to newer analogs (like Degludec or Glargine 300U) or adding SGLT2/GLP-1 agents with your doctor. These drugs are designed to work more smoothly, reducing dangerous lows and glucose spikes.
GoodSupportsHIGH confidence
Recent evidence supports the use of some glucose-lowering agents to improve GV, such as the new ultra-long acting insulin analogs, as these agents have a smoother pharmacodynamic profile and improve glycemic control with fewer fluctuations and fewer nocturnal hypoglycemic events.
Why this rating
Supported by specific trials (DEVOTE, VARIATION, Gla-300 vs Gla-100) cited in the review.
Source
A View Beyond HbA1c: Role of Continuous Glucose Monitoring
Haleh Chehregosha et al. · Diabetes Therapy · 2019
DOI 10.1007/s13300-019-0619-1
narrative_reviewCited 238×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Continuous Glucose Monitoring (CGM) metrics, specifically Time in Range (TIR) and Glycemic Variability (GV), provide superior clinical insight and safety compared to HbA1c alone by detecting hypoglycemia and glucose excursions that HbA1c misses.Good
- Glycemic Variability (GV), defined by a coefficient of variation (CV) >36%, is independently associated with an increased risk of hypoglycemia and diabetes-related complications, regardless of HbA1c levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →